PortalPublikationenIntra-Patient Heterogeneity of Circulating Tumor Cells and C...

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients

Standard

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. / Gorges, Katharina; Wiltfang, Lisa; Gorges, Tobias M; Sartori, Alexander; Hildebrandt, Lina; Keller, Laura; Volkmer, Beate; Peine, Sven; Babayan, Anna; Moll, Ingrid; Schneider, Stefan W; Twarock, Sören; Mohr, Peter; Fischer, Jens W; Pantel, Klaus.

in: CANCERS, Jahrgang 11, Nr. 11, 29.10.2019, S. 1685.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gorges, K, Wiltfang, L, Gorges, TM, Sartori, A, Hildebrandt, L, Keller, L, Volkmer, B, Peine, S, Babayan, A, Moll, I, Schneider, SW, Twarock, S, Mohr, P, Fischer, JW & Pantel, K 2019, 'Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients', CANCERS, Jg. 11, Nr. 11, S. 1685. https://doi.org/10.3390/cancers11111685

APA

Gorges, K., Wiltfang, L., Gorges, T. M., Sartori, A., Hildebrandt, L., Keller, L., Volkmer, B., Peine, S., Babayan, A., Moll, I., Schneider, S. W., Twarock, S., Mohr, P., Fischer, J. W., & Pantel, K. (2019). Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. CANCERS, 11(11), 1685. https://doi.org/10.3390/cancers11111685

Vancouver

Gorges K, Wiltfang L, Gorges TM, Sartori A, Hildebrandt L, Keller L et al. Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients. CANCERS. 2019 Okt 29;11(11):1685. https://doi.org/10.3390/cancers11111685

Bibtex

@article{beb79699f2844cdca0279de68b86236b,
title = "Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients",
abstract = "Despite remarkable progress in melanoma therapy, the exceptional heterogeneity of the disease has prevented the development of reliable companion biomarkers for the prediction or monitoring of therapy responses. Here, we show that difficulties in detecting blood-based markers, like circulating tumor cells (CTC), might arise from the translation of the mutational heterogeneity of melanoma cells towards their surface marker expression. We provide a unique method, which enables the molecular characterization of clinically relevant CTC subsets, as well as circulating tumor DNA (ctDNA), from a single blood sample. The study demonstrates the benefit of a combined analysis of ctDNA and CTC counts in melanoma patients, revealing that CTC subsets and ctDNA provide synergistic real-time information on the mutational status, RNA and protein expression of melanoma cells in individual patients, in relation to clinical outcome.",
author = "Katharina Gorges and Lisa Wiltfang and Gorges, {Tobias M} and Alexander Sartori and Lina Hildebrandt and Laura Keller and Beate Volkmer and Sven Peine and Anna Babayan and Ingrid Moll and Schneider, {Stefan W} and S{\"o}ren Twarock and Peter Mohr and Fischer, {Jens W} and Klaus Pantel",
year = "2019",
month = oct,
day = "29",
doi = "10.3390/cancers11111685",
language = "English",
volume = "11",
pages = "1685",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

RIS

TY - JOUR

T1 - Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients

AU - Gorges, Katharina

AU - Wiltfang, Lisa

AU - Gorges, Tobias M

AU - Sartori, Alexander

AU - Hildebrandt, Lina

AU - Keller, Laura

AU - Volkmer, Beate

AU - Peine, Sven

AU - Babayan, Anna

AU - Moll, Ingrid

AU - Schneider, Stefan W

AU - Twarock, Sören

AU - Mohr, Peter

AU - Fischer, Jens W

AU - Pantel, Klaus

PY - 2019/10/29

Y1 - 2019/10/29

N2 - Despite remarkable progress in melanoma therapy, the exceptional heterogeneity of the disease has prevented the development of reliable companion biomarkers for the prediction or monitoring of therapy responses. Here, we show that difficulties in detecting blood-based markers, like circulating tumor cells (CTC), might arise from the translation of the mutational heterogeneity of melanoma cells towards their surface marker expression. We provide a unique method, which enables the molecular characterization of clinically relevant CTC subsets, as well as circulating tumor DNA (ctDNA), from a single blood sample. The study demonstrates the benefit of a combined analysis of ctDNA and CTC counts in melanoma patients, revealing that CTC subsets and ctDNA provide synergistic real-time information on the mutational status, RNA and protein expression of melanoma cells in individual patients, in relation to clinical outcome.

AB - Despite remarkable progress in melanoma therapy, the exceptional heterogeneity of the disease has prevented the development of reliable companion biomarkers for the prediction or monitoring of therapy responses. Here, we show that difficulties in detecting blood-based markers, like circulating tumor cells (CTC), might arise from the translation of the mutational heterogeneity of melanoma cells towards their surface marker expression. We provide a unique method, which enables the molecular characterization of clinically relevant CTC subsets, as well as circulating tumor DNA (ctDNA), from a single blood sample. The study demonstrates the benefit of a combined analysis of ctDNA and CTC counts in melanoma patients, revealing that CTC subsets and ctDNA provide synergistic real-time information on the mutational status, RNA and protein expression of melanoma cells in individual patients, in relation to clinical outcome.

U2 - 10.3390/cancers11111685

DO - 10.3390/cancers11111685

M3 - SCORING: Journal article

C2 - 31671846

VL - 11

SP - 1685

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 11

ER -